32 Biosciences
Pioneering gut mucosal-immune science to prevent and treat gastrointestinal diseases
32 Biosciences develops first-in-class therapeutics and discovery diagnostics that protect and restore the gut mucosal-immune barrier. The company combines gut mucosal-immune science and metabolomic signatures to enable prevention, therapeutic discovery, development, and clinical decision support for gastrointestinal (GI) diseases.
Platforms and focus
32 Biosciences advances two complementary platforms:
- GI Discovery Platform — measures metabolomic signatures of the gut mucosal-immune system to enable therapeutic discovery, development, and clinical decision support (3 leading use cases).
- CS Therapeutic Platform — Mucosal Immune Modulator (MIM) therapeutics designed to restore and protect the mucosal-immune barrier in the GI tract. Lead asset: CS-0003 (7 indications targeted).
The company is focused on preventing and treating GI disease through novel therapeutics and a diagnostic discovery platform.